<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4720">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03323463</url>
  </required_header>
  <id_info>
    <org_study_id>17-409</org_study_id>
    <nct_id>NCT03323463</nct_id>
  </id_info>
  <brief_title>Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma</brief_title>
  <official_title>A Prospective Single Arm Non-inferiority Trial of Major Radiation Dose De-Escalation Concurrent With Chemotherapy for Human Papilloma Virus Associated Oropharyngeal Carcinoma (Major De-escalation to 30Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that participants with HPV positive and hypoxia&#xD;
      negative T1-2, N1-2c (AJCC, 7th ed.) oropharyngeal squamous cell carcinoma receiving a major&#xD;
      de-escalated radiation therapy with 2 cycles of standard chemotherapy is not inferior to&#xD;
      comparable subjects treated with the current standard chemoradiation.&#xD;
&#xD;
      Given there were restrictions of surgery during the COVID19 pandemic, we temporarily stopped&#xD;
      enrolling in Cohort A and started enrolling patients on Cohort B where surgery is not&#xD;
      required. When surgery was allowed, we stopped enrollment to Cohort B and resumed enrollment&#xD;
      to Cohort A and we are almost at target accrual for Cohort A where surgery is required.&#xD;
&#xD;
      During the COVID-19 pandemic, the research MRIs are optional.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2017</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of study treatment for participants receiving de-escalated radiation therapy radiation therapy, comparable to participants treated with the current standard of care chemoradiation by standard CT (or MRI) or tumor site and PET scan</measure>
    <time_frame>2 years (+/- 3 months)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>HPV-Associated Oropharyngeal Squamous Cell Carcinoma</condition>
  <condition>Squamous Cell Carcinoma of the Neck</condition>
  <arm_group>
    <arm_group_label>Arm A: HPV associated oropharyngeal carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPV associated oropharyngeal carcinoma subjects who also have no evidence of hypoxia. This arm is closed to accrual.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: HPV associated oropharyngeal carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPV associated oropharyngeal carcinoma subjects who also have no evidence of hypoxia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>F-FMISO PET/CT Scan</intervention_name>
    <description>Every participant will undergo a pre-treatment F-FMISO scan PET/CT scan pretreatment</description>
    <arm_group_label>Arm A: HPV associated oropharyngeal carcinoma</arm_group_label>
    <arm_group_label>Arm B: HPV associated oropharyngeal carcinoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>30 Gy over 3 weeks</intervention_name>
    <description>Treatment will be delivered as one fraction per day on a standard 5 day per week schedule (excluding weekends and holidays), total of 30 Gy over 3 weeks at 2 Gy per fraction each day. The gross nodes, the postoperative bed, all subclinical areas at risk for disease will receive the same dose at 30Gy.</description>
    <arm_group_label>Arm A: HPV associated oropharyngeal carcinoma</arm_group_label>
    <arm_group_label>Arm B: HPV associated oropharyngeal carcinoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cycle 1 (week 1): At the start of week 1 of IMRT, subjects will receive cisplatin 100 mg/m2 intravenously. They may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2), typically on days 1 and 2, or as a single dose, typically on day 1.</description>
    <arm_group_label>Arm A: HPV associated oropharyngeal carcinoma</arm_group_label>
    <arm_group_label>Arm B: HPV associated oropharyngeal carcinoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). Cycle 2 (Week 4): After the three weeks of radiation at week 4 when the subject no longer is receiving radiation therapy, subjects will receive cisplatin 100 mg/m2 intravenously. The may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2), typically on days 22 and 23, or as a single dose, typically on day 22.</description>
    <arm_group_label>Arm A: HPV associated oropharyngeal carcinoma</arm_group_label>
    <arm_group_label>Arm B: HPV associated oropharyngeal carcinoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5Fluorouracil</intervention_name>
    <description>If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).</description>
    <arm_group_label>Arm A: HPV associated oropharyngeal carcinoma</arm_group_label>
    <arm_group_label>Arm B: HPV associated oropharyngeal carcinoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Therapy</intervention_name>
    <description>Proton beam using pencil beam delivery either with the Varian or IBA delivery systems will be allowed for Cohort B. Proton beam therapy will be given at the New York Proton Center in New York City, where MSKCC has a well-established business associate agreement and cooperative research agreement with, respectively. If treatment at NYPC is not feasible, patients may be referred to ProCure in Somerset, NJ.</description>
    <arm_group_label>Arm B: HPV associated oropharyngeal carcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Cohort A: Pathologically (histologically or cytologically) proven diagnosis of HPV&#xD;
        associated squamous cell carcinoma of the oropharynx (tonsil, base of tongue, or&#xD;
        oropharyngeal walls) from surgical resection or excisional biopsy regardless of margin&#xD;
        status.&#xD;
&#xD;
          -  Squamous cell carcinoma of the neck of unknown primary is allowed with excision biopsy&#xD;
             of a lymph node (or core biopsy) and consent from the PI or co-PIs&#xD;
&#xD;
               -  Cohort B: Pathologic diagnosis can be from biopsy. Surgical removal of primary&#xD;
                  site is no longer required.&#xD;
&#xD;
          -  Squamous cell carcinoma of the neck of unknown primary is allowed with excision biopsy&#xD;
             of a lymph node (or core biopsy) and consent from the PI or co-PIs&#xD;
&#xD;
               -  Subjects must have clinically or radiographically evident measurable disease at&#xD;
                  nodal stations.&#xD;
&#xD;
               -  Clinical stage T1-2, N1-2c without evidence of distant metastasis based on FDG&#xD;
                  PET/CT.&#xD;
&#xD;
          -  Patients who have squamous cell carcinoma of the neck of unknown primary, and thus,&#xD;
             are T0, are allowed with excision biopsy of a lymph node (or core biopsy) or consent&#xD;
             from the PI or co-PI&#xD;
&#xD;
               -  CT or MRI of the neck with and without contrast Note: A CT scan of neck and/or a&#xD;
                  PET/CT performed for the purposes of radiation planning may serve as planning&#xD;
                  tools.&#xD;
&#xD;
               -  ECOG Performance Status of 0-2 or Karnopsky Performance Status &gt;/= 50&#xD;
&#xD;
               -  Age â‰¥ 18&#xD;
&#xD;
               -  Adequate hematologic function within 30 days prior to registration, defined as&#xD;
                  follows:&#xD;
&#xD;
          -  White Blood Count (WBC) &gt;/= 2 K/mcL&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) â‰¥ 1,000 cells/mm3&#xD;
&#xD;
          -  Platelets â‰¥ 100,000 cells/mm3&#xD;
&#xD;
          -  Hemoglobin â‰¥ 8.0 g/dl; Note: The use of transfusion or other intervention to achieve&#xD;
             Hgb â‰¥ 8.0 g/dl is acceptable&#xD;
&#xD;
               -  Adequate renal function within 30 days prior to registration, defined as follows:&#xD;
&#xD;
          -  Serum creatinine â‰¤ 1.5 mg/dl or creatinine clearance (CC) â‰¥ 50 ml/min determined by&#xD;
             24-hour collection or estimated by Cockcroft-Gault formula&#xD;
&#xD;
        CCr male = [(140 - age) x (wt in kg)] [(Serum Cr mg/dl) x (72)] CCr female = 0.85 x (CrCl&#xD;
        male)&#xD;
&#xD;
          -  Adequate hepatic function within 30 days prior to registration, defined as follows:&#xD;
&#xD;
               -  Bilirubin â‰¤ 2 mg/dl&#xD;
&#xD;
               -  AST or ALT â‰¤ 3 x the upper limit of normal&#xD;
&#xD;
          -  Negative serum pregnancy test within 14 days prior to registration for women of&#xD;
             childbearing potential&#xD;
&#xD;
          -  The subject must provide study-specific informed consent prior to study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with prior head and neck radiation therapy&#xD;
&#xD;
          -  Subjects with simultaneous primary cancers outside of the oropharynx&#xD;
&#xD;
          -  Note: Exceptions can be made for patients with simultaneous primaries outside the&#xD;
             oropharynx if determined by the PI/Co-PI the patient can proceed with protocol&#xD;
             activities&#xD;
&#xD;
          -  Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free&#xD;
             for 3 years or if cure rate from treatment at 5 years to be 90% or greater&#xD;
&#xD;
          -  Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a&#xD;
             different cancer is allowable&#xD;
&#xD;
          -  No particle therapy such as but not limited to proton therapy is allowed in Cohort A.&#xD;
             For Cohort B, this exclusion is removed.&#xD;
&#xD;
          -  Severe, active co-morbidity defined as follows:&#xD;
&#xD;
               -  Unstable angina and/or congestive heart failure requiring hospitalization within&#xD;
                  the last 6 months&#xD;
&#xD;
               -  Transmural myocardial infarction within the last 6 months&#xD;
&#xD;
               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the time&#xD;
                  of registration&#xD;
&#xD;
               -  Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness&#xD;
                  requiring hospitalization or precluding study therapy within 30 days of&#xD;
                  registration&#xD;
&#xD;
               -  Hepatic Insufficiency resulting in clinical jaundice and/or coagulation defects&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nancy Lee, MD</last_name>
    <phone>212-639-3341</phone>
    <email>leen2@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nadeem Riaz, MD</last_name>
    <phone>646-888-3495</phone>
    <email>RiazN@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Lee, MD</last_name>
      <phone>212-639-3341</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Lee, MD</last_name>
      <phone>212-639-3341</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Lee, MD</last_name>
      <phone>212-639-3341</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Lee, MD</last_name>
      <phone>212-639-3341</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Lee, MD</last_name>
      <phone>212-639-3341</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Lee, MD</last_name>
      <phone>212-639-3341</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Rockville Centre</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Lee, MD</last_name>
      <phone>212-639-3341</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Lee, MD</last_name>
      <phone>212-639-3341</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>October 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2017</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>squamous cell carcinoma of the neck of unknown primary</keyword>
  <keyword>HPV-Associated Oropharyngeal Squamous Cell Carcinoma</keyword>
  <keyword>Oropharyngeal Squamous Cell Carcinoma</keyword>
  <keyword>17-409</keyword>
  <keyword>Hypoxia negative</keyword>
  <keyword>N1-2c oropharyngeal squamous cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

